Fernandez-Pombo, A.
Lorenzo, P. M.
Carreira, M. C.
Gomez-Arbelaez, D.
Castro, A. I.
Primo, D.
Rodriguez, J.
Sajoux, I.
Baltar, J.
de Luis, D.
Bellido, D.
Crujeiras, A. B. http://orcid.org/0000-0003-4392-0301
Casanueva, F. F.
Funding for this research was provided by:
Instituto de Salud Carlos III (PI20/00650, PI20/00628, CP17/00088, CPII22/00008)
Consellería de Economía, Emprego e Industria, Xunta de Galicia (IN607B2020/09)
Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia (IN606-2020/013)
Universidade de Santiago de Compostela
Article History
Received: 1 December 2023
Accepted: 14 March 2024
First Online: 2 May 2024
Declarations
:
: D. G-A., A.I.C., D.B., D. dL, A.B.C. and F.F.C. received advisory board fees and/or research grants from Pronokal group, Spain. I.S. is the Medical Director of Pronokal, Spain.
: This study was approved by the ethics review panels of Galicia (registry 2009/076) and the University Clinical Hospital of Valladolid Committee ref PI8/2017 (Spain). Moreover, part of this study, particularly regarding the VLCKD intervention, was registered as clinical trial (clinicaltrial.gov: NCT01865448).
: All subjects provided written informed consent for participation in the study and for the publication of their clinical and biochemical information.
: All procedures performed were in accordance with the 2013 Helsinki declaration and its later amendments.